American Journal Of Cardiovascular Drugs

Journal Title：American Journal Of Cardiovascular Drugs

Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents.

Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations.

The American Journal of Cardiovascular Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager?, supported by a database of international experts. This database is shared with other Adis journals.

《美國心血管藥物雜志》旨在促進心臟病學領域的合理治療，涵蓋了心血管疾病治療的各個方面，特別是新藥和成熟藥物在治療中的作用。

通過一系列評論和原創臨床研究文章，該雜志探討了與這些疾病治療相關的主要問題，包括主要藥物類別的藥理學、療效和不良反應；新開發藥物和藥物類別的信息；心血管疾病病因學最新研究的治療意義；以及特定臨床情況的實際管理。

《美國心血管藥物雜志》提供了一系列額外的增強功能，旨在提高雜志內容的可見性、讀者群和教育價值。每篇文章都附有要點摘要，為廣大讀者提供內容的省時概述。文章可能附有通俗易懂的語言摘要，以幫助患者、護理人員和其他人了解重要的醫學進展。該雜志還提供包括幻燈片集、視頻和動畫等各種其他類型的增強功能的選項。所有增強功能都經過同行評審，標準與文章本身一樣高。同行評審使用 Editorial Manager? 進行，由國際專家數據庫支持。該數據庫與其他 Adis 期刊共享。

American Journal Of Cardiovascular Drugs創刊于2001年，由Springer International Publishing出版商出版，收稿方向涵蓋醫學 - 心血管系統全領域，此期刊水平偏中等偏靠后，在所屬細分領域中專業影響力一般，過審相對較易，如果您文章質量佳，選擇此期刊，發表機率較高。平均審稿速度 12周，或約稿 ，影響因子指數2.8，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。